Signal from the log
Vaderis Therapeutics
152 M$ · Series B · Switzerland · Biotech
Biotech suisse qui développe l'engasertib contre la télangiectasie hémorragique héréditaire, une maladie vasculaire génétique rare pour laquelle aucun traitement n'est approuvé nulle part dans le monde. Le tour finance l'essai mondial de phase 3 HEROIC, engagé au même moment.
Verified
Announced on , logged by the watch of 11 August 2026.
- Operation
- Funding round
- Announced amount
- 152 M$
- Stage
- Series B
- Country
- Switzerland
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Life Sciences at Goldman Sachs Alternatives , TCGX , with Omega Funds , EQT Life Sciences , Perceptive Advisors , Kalehua Capital , Medicxi , Droia Ventures
Provenance
Source prnewswire
Logged on 11 August 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.